Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807221 · ClinicalTrials.gov registry record · Phase 2
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,066
- Enrollment target
NCT01807221 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 1,066 participants.
The verdict
NCT01807221, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,066 participants
- Enrollment target
Study Summary
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic kidney disease or kidney disease alone. These treatment doses were compared to eplerenone, another marketed drug approved to treat heart failure.
Interventions
- DRUG Placebo
- DRUG Finerenone (BAY94-8862)
- DRUG Inspra (eplerenone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,066 participants |
| Start Date | 2013-06-17 |
| Est. Completion | 2014-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807221
The ClinicalTrials.gov registry entry for NCT01807221 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,066 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01807221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807221 about?
NCT01807221 is a clinical study titled "Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone". To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic kidney disease or kidney disease alone. These treatment doses were compa...
What is the current status of trial NCT01807221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,066 participants. The study started on 2013-06-17. Estimated completion is 2014-12-09.
What interventions are being tested in trial NCT01807221?
The interventions under investigation include: Placebo (DRUG), Finerenone (BAY94-8862) (DRUG), Inspra (eplerenone) (DRUG).
Who is sponsoring clinical trial NCT01807221?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.